Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

Investigating the use of peptide inhibitors to reduce alpha-synuclein aggregation-related protein-protein interactions

EF 2025-26

Résumé
Parkinsons’ Disease (PD) is a movement disorder marked by the breakdown of the neurons in the brain that produce a chemical messenger called dopamine. This in turn causes a person’s body movements to slow down. Given that the exact cause of the dopamine neurons breakdown in PD is unknown, it is difficult to develop treatments. One characteristic of PD is when a protein in the neurons called A-synuclein (A-syn) misfolds and forms clumps. While A-syn’s normal function helps to transport dopamine, in PD it contributes to decreased dopamine signalling. Therefore, preventing A-syn from accumulating may be a potential treatment option for PD. A-syn clumps are known to form when another protein in the neuron called CHMP2B interacts with A-syn. The Kalia lab has found a way to reduce this interaction by developing a small molecule called PDpep1.3. However, it is difficult to get PDpep1.3 into neurons because of the protective properties of the blood-brain barrier (BBB) and the neuronal membrane. Both the BBB and neuronal membrane are highly selective when determining which substances can enter or exit the brain environs. To bypass the BBB, a delivery system known as transmigrating single-domain antibody fragments or VHHs, has been developed. However, a PDpep1.3-VHH combination has not been tested on its ability to enter primary cortical neurons, which are neurons harvested from the brain tissue of an animal. The current project aims to test PDpep1.3 in combination with different VHHs to determine which combination can successfully enter primary cortical neurons. The ability of PDpep1.3 to reduce the interaction between A-syn and CHMP2B after entry into the neuron via VHHs will also be evaluated. Our goal is to use PDpep1.3 to help identify a target for PD treatments.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
573121
Name
Borenstein Adina
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the use of peptide inhibitors to reduce alpha-synuclein aggregation-related protein-protein interactions
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Alpha-Synuclein; Blood-Brain Barrier; Fusion Proteins; Neurodegenration; Parkinson'S Disease; Pdpep1.3; Primary Cortical Neurons; Protein-Protein Interactions; Proximal Ligation Assay; Transmigrating Single-Domain Antibody Fragments
Abstract
Parkinsons’ Disease (PD) is a movement disorder marked by the breakdown of the neurons in the brain that produce a chemical messenger called dopamine. This in turn causes a person’s body movements to slow down. Given that the exact cause of the dopamine neurons breakdown in PD is unknown, it is difficult to develop treatments. One characteristic of PD is when a protein in the neurons called A-synuclein (A-syn) misfolds and forms clumps. While A-syn’s normal function helps to transport dopamine, in PD it contributes to decreased dopamine signalling. Therefore, preventing A-syn from accumulating may be a potential treatment option for PD. A-syn clumps are known to form when another protein in the neuron called CHMP2B interacts with A-syn. The Kalia lab has found a way to reduce this interaction by developing a small molecule called PDpep1.3. However, it is difficult to get PDpep1.3 into neurons because of the protective properties of the blood-brain barrier (BBB) and the neuronal membrane. Both the BBB and neuronal membrane are highly selective when determining which substances can enter or exit the brain environs. To bypass the BBB, a delivery system known as transmigrating single-domain antibody fragments or VHHs, has been developed. However, a PDpep1.3-VHH combination has not been tested on its ability to enter primary cortical neurons, which are neurons harvested from the brain tissue of an animal. The current project aims to test PDpep1.3 in combination with different VHHs to determine which combination can successfully enter primary cortical neurons. The ability of PDpep1.3 to reduce the interaction between A-syn and CHMP2B after entry into the neuron via VHHs will also be evaluated. Our goal is to use PDpep1.3 to help identify a target for PD treatments.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Borenstein, Adina
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~